130 Views | 70 Downloads
Christopher B. Doering, Aflac Cancer and Blood Disorders Center, Emory University, 2015 Uppergate Drive NE Rm 450, Atlanta, GA 30322. Email: cdoerin@emory.edu
H.T.S., E.A.G., and C.B.D. conceived the project. P.L., H.T.S., and C.B.D. designed the experiments and analyzed the data; K.A.K., C.W.C., C.E.R., A.F., J.M.S., E.T.P., G.D., F.S., R.M.S., A.P., and M.C. performed experiments and analyzed the data; K.A.K. and C.B.D. drafted the manuscript; and K.A.K., P.L., E.A.G., H.T.S., and C.B.D. edited the manuscript.
This work was supported by grants HL137128 (H.T.S., C.B.D.) and U54 HL141981 (P.L.) from the National Heart, Lung and Blood Institute, National Institutes of Health (NIH); grant R01AR069137 (E.A.G.) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH; and grant RGP0041 (E.A.G.) from the Human Frontier Science Program.
C.E.R., H.T.S., E.A.G., and C.B.D. are inventors on a patent application describing the ancestral FIX technology filed by Emory University, Children’s Healthcare of Atlanta, and Georgia Institute of Technology. H.T.S. and C.B.D. are inventors on a patent for liver-directed codon-optimization and promoter technology filed by Emory University and Children’s Healthcare of Atlanta. H.T.S. and C.B.D. are cofounders of Expression Therapeutics and own equity in the company. Expression Therapeutics has obtained licenses for the ancestral FIX, liver codon optimized FIX, and synthetic liver-directed promoter intellectual property. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its conflict of interest policies. The remaining authors declare no competing financial interests.
© 2021 by The American Society of Hematology